In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Aptevo Therapeutics, Inc.. Trade Record

NASDAQ:APVO Aptevo Therapeutics, Inc. stock gains 7.38% Exit Feb 12, 2019 a Trade Record by priceseries

Trade Chart
Trade Chart APVO Jan 31, 2019, priceSeries
About Aptevo Therapeutics, Inc.

Aptevo Therapeutics Inc., a biotechnology company, provides oncology and hematology therapeutics. Its marketed products include WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn; and HepaGam B used for the prevention of hepatitis-B recurrence following liver transplantation in HBsAg-positive liver transplant patients, and for the treatment following exposure to hepatitis-B. The company's marketed products also comprise VARIZIG for use in treating following exposure to varicella zoster virus, which causes chickenpox in high-risk individuals; and IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its investigational stage product candidates include MOR209/ES414, ES210, ES425, and otlertuzumab used to expand on the utility and effectiveness of therapeutic antibodies; and 5E3 mAb, a monoclonal antibody therapeutic that is in pre-clinical development for Alzheimer's disease. The company was incorporated in 2016 and is based in Seattle, Washington. As of August 01, 2016, Aptevo Therapeutics Inc. operates independently of Emergent BioSolutions, Inc.

Trade Information
Trade Type
LONG
ReliabilityScore™
99.60
Entry Date
Jan 31, 2019
Entry Price
1.60
Sell Date
Feb 12, 2019
Sell Price
1.72
Net Gain
7.38%
Hold Time
8 Trading Days